Ding Dong is the Skinny Label (Effectively) Dead?
FDA Law Blog
SEPTEMBER 6, 2021
Teva case, that the statutory provisions governing patent infringement, specifically induced infringement, do not address carve-outs. Instead, it was GSK who erred in omitting the post-MI language from the use code. Especially now with the utility of the use code minimized. The catch is, as we have learned from the GSK v.
52 
Let's personalize your content